BEIJING, March 01, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), for the treatment of pediatric patients (aged 2 to 12) with solid tumors harboring NTRK gene fusions. Priority review is one of the key policies introduced by the CDE to accelerate drug approval. Read More
Source link
Catherine O’Hara wins posthumous SAG-AFTRA Actor Award for ‘The Studio’
IE 11 is not supported. For an optimal experience visit our site on another browser. Now Playing Catherine O’Hara wins posthumous SAG-AFTRA Actor Award for ‘The Studio’ 01:21 UP NEXT…






